1616298-75-9

Upstream product

• 122376-76-5 2-(3,5-difluorophenyl)acetonitrile 
• 51229-51-7 4-acetylbenzyl bromide 

Downstream Products

• 1616298-83-9 6-(3,5-difluorobenzyl)-5-iodo-2-((4-acetylbenzyl)thio)pyrimidin-4(3H)-one 

Relevant academic research and scientific papers

With anti-HBV virus is HCV virus anti-HIV and a new class of the role of non-nucleoside S-DABOs pyrimdinone derivatives, their preparation and use

The invention relates to non-nucleoside S-DABOs pyrimidone derivatives having both anti-HBV activity and anti-HIV and anti-HCV activities. The non-nucleoside S-DABOs pyrimidone derivatives have the chemical structure represented by the general formula I, wherein definitions of the groups are defined in the claims. The new compounds obtained by chemical synthesis adopt non-nucleoside pyrimidone as a mother nucleus; the drug resistance is not easily produced when HBV is inhibited, and a mechanism of competing with a body substrate is avoided, so the compounds have relatively small toxic or side effect. At the same time, the new synthesized compounds also have a certain inhibition effect on HIV and HCV. The general formula I is shown in the description, wherein R1 is H, CH3 or F; R2 is (p-NO2)C6H5CH2, (p-CN)C6H5CH2, (p-CH3CO)C6H5CH2, (p-CH3OOC)C6H5CH2, (p-NO2) C6H5OCH2CH2, (p-NO2)C6H5CH2CH2, C6H5OCH2CH2CH2, C6H5CH2OCH2, (p-NO2)C6H5CH2CH2CH2, (p-NH2))C6H5CH2CH2CH2, (p-NHAc)C6H5CH2CH2, or (p-NHAc) C6H5CH2CH2CH2; and R3 is H or I.

Synthesis and biological evaluation of novel 2-Arylalkylthio-5-iodine-6- substituted-benzyl-pyrimidine-4(3H)-ones as Potent HIV-1 Non-Nucleoside reverse transcriptase inhibitors

A novel series of 2-arylalkylthio-5-iodine-6-substitutedbenzyl-pyrimidine- 4(3H)- ones (S-DABOs) 8a-x had been synthesized via an efficient method. Their biological activity against HIV virus and RT assay were evaluated. Some compounds, especially 8h, 8l and 8n, displayed promising activity against HIV-1 RT with IC50 values in a range of 0.41 μM to 0.71 iM, which were much better than that of nevirapine. Molecular modeling studies revealed that the binding mode would be affected via forming an additional hydrogen bond by incorporating an oxygen atom on the C-2 side chain. The biological activity was in accordance with the docking results.